Interventional News’ top 10 most popular stories of October 2023


TOP 10Interventional News’ most read stories in October included significant data releases from TCT 2023 (23–26 October, San Francisco, USA); results from a study investigating sex disparities in outcomes post-TCAR; among several device updates.

1. Cryoablation found to “significantly reduce pain” in endometriosis patients with abdominal wall lesions

Published in the Journal of Vascular and Interventional Radiology, a recent retrospective study which evaluated pain relief after percutaneous image-guided cryoablation in patients with symptomatic extraperitoneal endometriosis (EE), has found the treatment to be “safe and effective”.

2. ABK Biomedical announce first patient treated in Y90 radioembolization study

ABK Biomedical, a medical device company dedicated to the research, development, and commercialisation of advanced imageable embolic medical devices, has announced the first patient treated in its Route90 US investigation device exemption (IDE) pivotal study.

3. Rates of stroke, death and myocardial infarction post-TCAR do not differ by patient sex

While sex disparities regarding the outcomes of carotid revascularisation have “long been a concern”, new prospective data published in the Journal of Vascular Surgery (JVS) indicate that no such disparity exists between male and female patients treated with transcarotid artery revascularisation (TCAR; Silk Road Medical)—one of the most prominent approaches used to treat carotid artery stenosis.

4. TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries

Results of the LIFE-BTK randomised controlled trial have just been presented at TCT 2023. The data show that, in patients with chronic limb-threatening ischaemia (CLTI) due to infrapopliteal artery disease, an everolimus-eluting resorbable scaffold was superior to angioplasty at one year with respect to the primary efficacy endpoint.

5. TCT 2023: First presentation of complete patient-level dataset on paclitaxel and death that helped sway the US FDA

Data from a patient-level meta-analysis—a factor in the US Food and Drug Administration’s (FDA) recent change of position on the use of paclitaxel-coated devices to treat peripheral arterial disease (PAD)—have been made public for the first time at TCT 2023 (23–26 October, San Francisco, USA).

6. REAL-PE demonstrates statistically significant lower major bleeding rates with Ekos system compared to mechanical thrombectomy for PE treatment

Data from the REAL-PE study were presented at TCT 2023 (23–26 October, San Francisco, USA) demonstrating that patients treated for pulmonary embolism (PE) with the Ekos endovascular system (Boston Scientific) had lower rates of adverse events, including statistically significant lower rates of major bleeding, within seven days following their procedure compared to the FlowTriever system (Inari Medical).

7. Robocath completes CARE clinical trial evaluating robotic carotid stenting

Robocath has announced the results of its CARE clinical trial focusing on robotic carotid stenting—the first phase of a research programme launched in July 2021 by Robocath and Rennes University Hospital (Rennes, France), which, in the long term, is aiming to enhance current and future generations of robots used in the treatment of neurovascular diseases.

8. Cardio Flow announces US FDA 510(k) clearance for its FreedomFlow orbital atherectomy peripheral platform

Cardio Flow announced it has received US Food and Drug Administration (FDA) 510(k) clearance for the company’s FreedomFlow orbital atherectomy peripheral platform. The company details in a press release that the FreedomFlow platform is designed with a modern mechanism of action to clear plaque blockages in the arteries of the legs.

9. Merit Medical announces expanded microcatheter line for radial embolization

Merit Medical Systems, a leading global manufacturer and marketer of healthcare technology, has announced the expansion of its Maestro microcatheter product line to now include a new longer length for radial embolization procedures.

10. Delcath Systems announces publication of study comparing chemosaturation and SIRT

Delcath Systems, an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, have announced the publication of an article entitled ‘Selective internal radiotherapy (SIRT) and chemosaturation percutaneous hepatic perfusion (CS-PHP) for metastasized uveal melanoma: A retrospective comparative study” in the peer-reviewed oncology journal Cancers.


Please enter your comment!
Please enter your name here